Zegocractin

Zegocractin
Identifiers
	IUPAC name N-[5-(6-chloro-2,2-difluoro-1,3-benzodioxol-5-yl)pyrazin-2-yl]-2-fluoro-6-methylbenzamide;
CAS Number	1713240-67-5 ;
PubChem CID	122507647;
DrugBank	DB16466;
ChemSpider	58810276;
UNII	564AW1RR37;
KEGG	D13009;
Chemical and physical data
Formula	C19H11ClF3N3O3
Molar mass	421.76 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C(=CC=C1)F)C(=O)NC2=NC=C(N=C2)C3=CC4=C(C=C3Cl)OC(O4)(F)F;
	InChI InChI=1S/C19H11ClF3N3O3/c1-9-3-2-4-12(21)17(9)18(27)26-16-8-24-13(7-25-16)10-5-14-15(6-11(10)20)29-19(22,23)28-14/h2-8H,1H3,(H,25,26,27); Key:QQMKTHUGOQDEIL-UHFFFAOYSA-N;

Zegocractin (development code CM-4620) is a drug which acts as a selective inhibitor of the calcium channel ORAI1. It inhibits store-operated calcium entry (SOCE) and has anti-inflammatory effects. It is being researched for the treatment of pancreatitis^[1], including acute pancreatitis associated with systemic inflammatory response syndrome (completed phase 2b CARPO trial^[2]).

References

↑ Waldron RT, Chen Y, Pham H, Go A, Su HY, Hu C, et al. (June 2019). "The Orai Ca2+ channel inhibitor CM4620 targets both parenchymal and immune cells to reduce inflammation in experimental acute pancreatitis". The Journal of Physiology. 597 (12): 3085–3105. doi:10.1113/JP277856. PMC 6582954. PMID 31050811.
↑ Sutton R, Garg PK, Miller J, Kumar SS, Buxbaum JL, Philip M, Zhang J, Stauderman K, Hebbar S, Wu BU, Peacock WF, Gardner TB. "Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial". eClinicalMedicine. 93: 103757. doi:10.1016/j.eclinm.2026.103757.{{cite journal}}: CS1 maint: article number as page number (link)